Document is current

Article History

Received: 23 June 2022

Accepted: 27 October 2023

First Online: 20 November 2023

Declarations

:

: This study, a retrospective analysis of the data collected from a quality improvement (QI) project, was approved by Biomedical Research Alliance of New York Institutional Review Board (BRANY IRB), under the protocol number BRANY #21–12-196–599. BRANY IRB determined the research exempt from IRB review under category # 4(ii), as detailed in 45 CFR 46.104(d). BRANY IRB determined that the study qualified as secondary research for which consent is not required, as it fulfilled the following requirement: “Secondary research uses of identifiable private information or identifiable biospecimens, with the following criterion met:(ii) Information, which may include information about biospecimens, is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects.”

: Not applicable.

: All authors are or were full-time employees of and have stock options in Ro, the telehealth company that provided the data for this study.